News Genmab A/S Nasdaq

Equities

GMAB

US3723032062

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-10 pm EDT			5-day change	1st Jan Change
25.71 ^USD	+0.27%		+2.23%	-19.25%

Jul. 10	Markets Powered by Alternating Current
Jul. 08	Myricx Pharma Ltd announced that it has received £90 million in funding from a group of investors	CI

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Markets Powered by Alternating Current	Jul. 10
Non-Hodgkin Lymphoma Pipeline 2024 \| Novartis, AstraZeneca, Genentech, BioInvent, Genmab, SystImmune, Nordic Nanovector, Pacylex Pharmaceuticals, Artiva Biotherapeutics, Inc., Chipscreen Biosciences	Jul. 09	AQ
Myricx Pharma Ltd announced that it has received £90 million in funding from a group of investors	Jul. 07	CI
Myricx Bio announced that it has received £90 million in funding from a group of investors	Jul. 07	CI
Genmab A/S - Epcoritamab Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed, Refractory Follicular Lymphoma	Jul. 01	AQ
Genmab A/S - Completion of Share Buy-back Program	Jun. 28	AQ
Would you like some more inflation?	Jun. 28
Genmab, AbbVie's Lymphoma Therapy Recommended for Approval in EU	Jun. 28	MT
AbbVie, Genmab Receive Positive European Opinion on Marketing Authorization for Possible Lymphoma Treatment	Jun. 28	MT
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma	Jun. 28	BU
Epcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for the Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma	Jun. 28	GL
Genmab A/S Announces Epcoritamab Receives Positive CHMP Opinion for Treatment of Adults with Relapsed/ Refractory Follicular Lymphoma	Jun. 28	CI
AbbVie Receives Positive CHMP Opinion for Epcoritamab for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma	Jun. 28	CI
Genmab Closes DKK3.5 Billion Share Buyback Early	Jun. 28	MT
Completion of Share Buy-back Program	Jun. 27	GL
Genmab A/S - EPKINLY Approved by U.S. FDA for Patients with Relapsed or Refractory Follicular Lymphoma	Jun. 27	AQ
AbbVie - U.S. Food and Drug Administration Grants Second Approval for EPKINLY to Treat Patients with Relapsed or Refractory Follicular Lymphoma	Jun. 27	AQ
BTIG Adjusts Price Target on Genmab to $47 From $46, Maintains Buy Rating	Jun. 27	MT
Genmab Gets FDA Approval for Follicular Lymphoma Treatment	Jun. 27	MT
Genmab Wins US Approval for Follicular Lymphoma Treatment	Jun. 27	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

GENMAB : A good start to 2024; guidance unchanged

May 03, 2024 at 01:08 pm EDT